Report Detail

Pharma & Healthcare Global Autologous Matrix-induced Chondrogenesis Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • RnM2766273
  • |
  • 14 January, 2019
  • |
  • Global
  • |
  • 120 Pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

utologous matrix-induced chondrogenesis (AMIC) is a 1-step cartilage restoration technique that combines microfracture with the use of an exogenous scaffold.

Scope of the Report:
This report focuses on the Autologous Matrix-induced Chondrogenesis in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The functional principle of microfracturing is based on the release of multipotent mesenchymal progenitor cells, cytokines and growth factors from the subchondral bone. 
The worldwide market for Autologous Matrix-induced Chondrogenesis is expected to grow at a CAGR of roughly 8.0% over the next five years, will reach 160 million US$ in 2023, from 100 million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers
JRI Orthopaedics Ltd
BioTissue
Anika Therapeutics
B. Braun Melsungen
Arthro-Kinetics
Geistlich Pharma
CartiHeal
Matricel
Smith & Nephew
Zimmer Biomet Holdings

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Hyaluronic Acid
Collagen
Polyethylene Glycol (PEG)
Poly Lactic-Co-Glycolic Acid (PGLA)

Market Segment by Applications, can be divided into
Knees Joint
Other

There are 15 Chapters to deeply display the global Autologous Matrix-induced Chondrogenesis market.
Chapter 1, to describe Autologous Matrix-induced Chondrogenesis Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Autologous Matrix-induced Chondrogenesis, with sales, revenue, and price of Autologous Matrix-induced Chondrogenesis, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Autologous Matrix-induced Chondrogenesis, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Autologous Matrix-induced Chondrogenesis market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Autologous Matrix-induced Chondrogenesis sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source


Table of Contents

    1 Market Overview

    • 1.1 Autologous Matrix-induced Chondrogenesis Introduction
    • 1.2 Market Analysis by Type
      • 1.2.1 Hyaluronic Acid
      • 1.2.2 Collagen
      • 1.2.3 Polyethylene Glycol (PEG)
      • 1.2.4 Poly Lactic-Co-Glycolic Acid (PGLA)
    • 1.3 Market Analysis by Applications
      • 1.3.1 Knees Joint
      • 1.3.2 Other
    • 1.4 Market Analysis by Regions
      • 1.4.1 North America (United States, Canada and Mexico)
        • 1.4.1.1 United States Market States and Outlook (2013-2023)
        • 1.4.1.2 Canada Market States and Outlook (2013-2023)
        • 1.4.1.3 Mexico Market States and Outlook (2013-2023)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
        • 1.4.2.1 Germany Market States and Outlook (2013-2023)
        • 1.4.2.2 France Market States and Outlook (2013-2023)
        • 1.4.2.3 UK Market States and Outlook (2013-2023)
        • 1.4.2.4 Russia Market States and Outlook (2013-2023)
        • 1.4.2.5 Italy Market States and Outlook (2013-2023)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        • 1.4.3.1 China Market States and Outlook (2013-2023)
        • 1.4.3.2 Japan Market States and Outlook (2013-2023)
        • 1.4.3.3 Korea Market States and Outlook (2013-2023)
        • 1.4.3.4 India Market States and Outlook (2013-2023)
        • 1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
      • 1.4.4 South America, Middle East and Africa
        • 1.4.4.1 Brazil Market States and Outlook (2013-2023)
        • 1.4.4.2 Egypt Market States and Outlook (2013-2023)
        • 1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
        • 1.4.4.4 South Africa Market States and Outlook (2013-2023)
        • 1.4.4.5 Nigeria Market States and Outlook (2013-2023)
    • 1.5 Market Dynamics
      • 1.5.1 Market Opportunities
      • 1.5.2 Market Risk
      • 1.5.3 Market Driving Force

    2 Manufacturers Profiles

    • 2.1 JRI Orthopaedics Ltd
      • 2.1.1 Business Overview
      • 2.1.2 Autologous Matrix-induced Chondrogenesis Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 JRI Orthopaedics Ltd Autologous Matrix-induced Chondrogenesis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    • 2.2 BioTissue
      • 2.2.1 Business Overview
      • 2.2.2 Autologous Matrix-induced Chondrogenesis Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 BioTissue Autologous Matrix-induced Chondrogenesis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    • 2.3 Anika Therapeutics
      • 2.3.1 Business Overview
      • 2.3.2 Autologous Matrix-induced Chondrogenesis Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Anika Therapeutics Autologous Matrix-induced Chondrogenesis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    • 2.4 B. Braun Melsungen
      • 2.4.1 Business Overview
      • 2.4.2 Autologous Matrix-induced Chondrogenesis Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 B. Braun Melsungen Autologous Matrix-induced Chondrogenesis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    • 2.5 Arthro-Kinetics
      • 2.5.1 Business Overview
      • 2.5.2 Autologous Matrix-induced Chondrogenesis Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Arthro-Kinetics Autologous Matrix-induced Chondrogenesis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    • 2.6 Geistlich Pharma
      • 2.6.1 Business Overview
      • 2.6.2 Autologous Matrix-induced Chondrogenesis Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Geistlich Pharma Autologous Matrix-induced Chondrogenesis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    • 2.7 CartiHeal
      • 2.7.1 Business Overview
      • 2.7.2 Autologous Matrix-induced Chondrogenesis Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 CartiHeal Autologous Matrix-induced Chondrogenesis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    • 2.8 Matricel
      • 2.8.1 Business Overview
      • 2.8.2 Autologous Matrix-induced Chondrogenesis Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Matricel Autologous Matrix-induced Chondrogenesis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    • 2.9 Smith & Nephew
      • 2.9.1 Business Overview
      • 2.9.2 Autologous Matrix-induced Chondrogenesis Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Smith & Nephew Autologous Matrix-induced Chondrogenesis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    • 2.10 Zimmer Biomet Holdings
      • 2.10.1 Business Overview
      • 2.10.2 Autologous Matrix-induced Chondrogenesis Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Zimmer Biomet Holdings Autologous Matrix-induced Chondrogenesis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    3 Global Autologous Matrix-induced Chondrogenesis Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

    • 3.1 Global Autologous Matrix-induced Chondrogenesis Sales and Market Share by Manufacturer (2016-2017)
    • 3.2 Global Autologous Matrix-induced Chondrogenesis Revenue and Market Share by Manufacturer (2016-2017)
    • 3.3 Market Concentration Rate
      • 3.3.1 Top 3 Autologous Matrix-induced Chondrogenesis Manufacturer Market Share in 2017
      • 3.3.2 Top 6 Autologous Matrix-induced Chondrogenesis Manufacturer Market Share in 2017
    • 3.4 Market Competition Trend

    4 Global Autologous Matrix-induced Chondrogenesis Market Analysis by Regions

    • 4.1 Global Autologous Matrix-induced Chondrogenesis Sales, Revenue and Market Share by Regions
      • 4.1.1 Global Autologous Matrix-induced Chondrogenesis Sales and Market Share by Regions (2013-2018)
      • 4.1.2 Global Autologous Matrix-induced Chondrogenesis Revenue and Market Share by Regions (2013-2018)
    • 4.2 North America Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 4.3 Europe Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 4.4 Asia-Pacific Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 4.5 South America Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 4.6 Middle East and Africa Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)

    5 North America Autologous Matrix-induced Chondrogenesis by Countries

    • 5.1 North America Autologous Matrix-induced Chondrogenesis Sales, Revenue and Market Share by Countries
      • 5.1.1 North America Autologous Matrix-induced Chondrogenesis Sales and Market Share by Countries (2013-2018)
      • 5.1.2 North America Autologous Matrix-induced Chondrogenesis Revenue and Market Share by Countries (2013-2018)
    • 5.2 United States Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 5.3 Canada Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 5.4 Mexico Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)

    6 Europe Autologous Matrix-induced Chondrogenesis by Countries

    • 6.1 Europe Autologous Matrix-induced Chondrogenesis Sales, Revenue and Market Share by Countries
      • 6.1.1 Europe Autologous Matrix-induced Chondrogenesis Sales and Market Share by Countries (2013-2018)
      • 6.1.2 Europe Autologous Matrix-induced Chondrogenesis Revenue and Market Share by Countries (2013-2018)
    • 6.2 Germany Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 6.3 UK Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 6.4 France Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 6.5 Russia Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 6.6 Italy Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)

    7 Asia-Pacific Autologous Matrix-induced Chondrogenesis by Countries

    • 7.1 Asia-Pacific Autologous Matrix-induced Chondrogenesis Sales, Revenue and Market Share by Countries
      • 7.1.1 Asia-Pacific Autologous Matrix-induced Chondrogenesis Sales and Market Share by Countries (2013-2018)
      • 7.1.2 Asia-Pacific Autologous Matrix-induced Chondrogenesis Revenue and Market Share by Countries (2013-2018)
    • 7.2 China Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 7.3 Japan Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 7.4 Korea Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 7.5 India Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 7.6 Southeast Asia Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)

    8 South America Autologous Matrix-induced Chondrogenesis by Countries

    • 8.1 South America Autologous Matrix-induced Chondrogenesis Sales, Revenue and Market Share by Countries
      • 8.1.1 South America Autologous Matrix-induced Chondrogenesis Sales and Market Share by Countries (2013-2018)
      • 8.1.2 South America Autologous Matrix-induced Chondrogenesis Revenue and Market Share by Countries (2013-2018)
    • 8.2 Brazil Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 8.3 Argentina Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 8.4 Colombia Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)

    9 Middle East and Africa Autologous Matrix-induced Chondrogenesis by Countries

    • 9.1 Middle East and Africa Autologous Matrix-induced Chondrogenesis Sales, Revenue and Market Share by Countries
      • 9.1.1 Middle East and Africa Autologous Matrix-induced Chondrogenesis Sales and Market Share by Countries (2013-2018)
      • 9.1.2 Middle East and Africa Autologous Matrix-induced Chondrogenesis Revenue and Market Share by Countries (2013-2018)
    • 9.2 Saudi Arabia Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 9.3 UAE Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 9.4 Egypt Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 9.5 Nigeria Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)
    • 9.6 South Africa Autologous Matrix-induced Chondrogenesis Sales and Growth Rate (2013-2018)

    10 Global Autologous Matrix-induced Chondrogenesis Market Segment by Type

    • 10.1 Global Autologous Matrix-induced Chondrogenesis Sales, Revenue and Market Share by Type (2013-2018)
      • 10.1.1 Global Autologous Matrix-induced Chondrogenesis Sales and Market Share by Type (2013-2018)
      • 10.1.2 Global Autologous Matrix-induced Chondrogenesis Revenue and Market Share by Type (2013-2018)
    • 10.2 Hyaluronic Acid Sales Growth and Price
      • 10.2.1 Global Hyaluronic Acid Sales Growth (2013-2018)
      • 10.2.2 Global Hyaluronic Acid Price (2013-2018)
    • 10.3 Collagen Sales Growth and Price
      • 10.3.1 Global Collagen Sales Growth (2013-2018)
      • 10.3.2 Global Collagen Price (2013-2018)
    • 10.4 Polyethylene Glycol (PEG) Sales Growth and Price
      • 10.4.1 Global Polyethylene Glycol (PEG) Sales Growth (2013-2018)
      • 10.4.2 Global Polyethylene Glycol (PEG) Price (2013-2018)
    • 10.5 Poly Lactic-Co-Glycolic Acid (PGLA) Sales Growth and Price
      • 10.5.1 Global Poly Lactic-Co-Glycolic Acid (PGLA) Sales Growth (2013-2018)
      • 10.5.2 Global Poly Lactic-Co-Glycolic Acid (PGLA) Price (2013-2018)

    11 Global Autologous Matrix-induced Chondrogenesis Market Segment by Application

    • 11.1 Global Autologous Matrix-induced Chondrogenesis Sales Market Share by Application (2013-2018)
    • 11.2 Knees Joint Sales Growth (2013-2018)
    • 11.3 Other Sales Growth (2013-2018)

    12 Autologous Matrix-induced Chondrogenesis Market Forecast (2018-2023)

    • 12.1 Global Autologous Matrix-induced Chondrogenesis Sales, Revenue and Growth Rate (2018-2023)
    • 12.2 Autologous Matrix-induced Chondrogenesis Market Forecast by Regions (2018-2023)
      • 12.2.1 North America Autologous Matrix-induced Chondrogenesis Market Forecast (2018-2023)
      • 12.2.2 Europe Autologous Matrix-induced Chondrogenesis Market Forecast (2018-2023)
      • 12.2.3 Asia-Pacific Autologous Matrix-induced Chondrogenesis Market Forecast (2018-2023)
      • 12.2.4 South America Autologous Matrix-induced Chondrogenesis Market Forecast (2018-2023)
      • 12.2.5 Middle East and Africa Autologous Matrix-induced Chondrogenesis Market Forecast (2018-2023)
    • 12.3 Autologous Matrix-induced Chondrogenesis Market Forecast by Type (2018-2023)
      • 12.3.1 Global Autologous Matrix-induced Chondrogenesis Sales Forecast by Type (2018-2023)
      • 12.3.2 Global Autologous Matrix-induced Chondrogenesis Market Share Forecast by Type (2018-2023)
    • 12.4 Autologous Matrix-induced Chondrogenesis Market Forecast by Application (2018-2023)
      • 12.4.1 Global Autologous Matrix-induced Chondrogenesis Sales Forecast by Application (2018-2023)
      • 12.4.2 Global Autologous Matrix-induced Chondrogenesis Market Share Forecast by Application (2018-2023)

    13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
      • 13.1.1 Direct Marketing
      • 13.1.2 Indirect Marketing
      • 13.1.3 Marketing Channel Future Trend
    • 13.2 Distributors, Traders and Dealers

    14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology

      Summary:
      Get latest Market Research Reports on Autologous Matrix-induced Chondrogenesis . Industry analysis & Market Report on Autologous Matrix-induced Chondrogenesis is a syndicated market report, published as Global Autologous Matrix-induced Chondrogenesis Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023. It is complete Research Study and Industry Analysis of Autologous Matrix-induced Chondrogenesis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,480.00
      $5,220.00
      $6,960.00
      2,742.24
      4,113.36
      5,484.48
      3,201.60
      4,802.40
      6,403.20
      542,149.20
      813,223.80
      1,084,298.40
      290,092.80
      435,139.20
      580,185.60
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report